Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Investor Overview

Stock quote
  
 
VOLUME:
View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases
January 20, 2021
Aclaris Announces Pricing of Public Offering of Common Stock
January 19, 2021
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
View all »
Events
Jan 19, 2021
8:00 AM EST
Aclaris Therapeutics Presents Positive Preliminary Topline Data for ATI-450-RA-201
Dec 2, 2020
7:30 AM EST
Aclaris Therapeutics, Inc. at Evercore ISI 3rd Annual HealthCONx Conference
Sep 17, 2020
10:40 AM EDT
Aclaris Therapeutics, Inc. at Cantor Virtual Global Healthcare Conference
View all »
Feature Presentation
ATI-450-RA-201 Phase 2a Preliminary Topline Data Presentation

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.